A Quote by Scott Gottlieb

EpiPen is not unique. It falls into a category of old drugs, many of which should have long been subject to generic competition. — © Scott Gottlieb
EpiPen is not unique. It falls into a category of old drugs, many of which should have long been subject to generic competition.
The higher cost of getting a generic drug approved by regulators means that many old medicines don't face competitors. It's only after substantial price hikes that these drugs offer enough revenue to offset the rising generic entry costs, and start to entice competition.
Everyone is talking about sustainability and resilience, yet all that knowledge is thrown in the bin. [Lagos is] a unique case, but also a test case. It's unbelievably unique, but also it's now considered with a number of really generic opinions, generic solution, generic expectations.
I am deeply troubled by Mylan's misclassification of the EpiPen as a generic drug.
Many countries which are no longer able to afford their public health systems, which have made certain promises within their countries to purchase from free market or from other economies, are approaching us seeking help with the supply of generic drugs, which is opening a very big room of opportunity for us.
Drugs have destroyed many lives, but wrongheaded governmental policies have destroyed many more. I think it's obvious that after 40 years of war on drugs, it has not worked. There should be decriminalization of drugs.
Where there's a lack of competition - as we saw with Mylan Pharmaceutical's virtual monopoly on EpiPen - price increases often follow.
Country has just crossed so many lines now, that Skynyrd falls right into that category.
Biologics must be grown in living systems - fermented, for example, in large vats of bacteria cells. This makes them hard to replicate. For decades, biologics weren't subject to competition from copycat generic medicines, even once patents and exclusivities had lapsed on originals.
The same drugs are way cheaper in Germany than in America because, obviously, if all sickness funds negotiate with the drug companies for a single price, then the market power of the sickness funds is fully used. So therefore you would expect the prices to be lower for the drugs in Germany, and this is exactly what you see, at least for non-generic drugs.
A 'goto' in Perl falls into the category of hard things that should be possible, not easy things that should be easy.
When we find unjustified spikes in the prices of long-standing life-saving drugs, we should slap penalties on companies trying to cheat people who need those drugs!
What makes the EpiPen unique is its delivery vehicle - an auto-injector that's packaged in a convenient, pen-like device. The product's key attribute is its ability to reliably deliver accurate doses of the essential medicine.
It is not at all incredible, that a book which has been so long in the possession of mankind should contain many truths as yet undiscovered.
Brand-name drugs have no competition, since the government grants them very long, exclusive marketing rights.
I've been asked to do small parts in films, but you know, what I've learned in the 12 Steps of Recovery is that for me, being a public person, is not a very healthy thing. There's too many drugs, too many jets, too many girls, too many parties. It's just not my lifestyle. I'm 58 years old. A good round of golf is about as exciting as my life gets.
If there are still honest-smart men and women within those old and noble traditions, they should think carefully, observe and diagnose the illness. They should face the contradiction. Discuss the conflation. And then do as Warren Buffett and Bill Gates and many others have done. Choose the miracle of creative competition over an idolatry of cash. They should stand up.
This site uses cookies to ensure you get the best experience. More info...
Got it!